Genotype of CDC73 Germline Mutation Determines Risk of Parathyroid Cancer

Overview

Journal Endocr Relat Cancer

Specialties Endocrinology
Oncology

Date 2020 Jun 27

PMID 32590342

Citations 18

Authors

Yulong Li

Jianhua Zhang

Poorni R Adikaram

James Welch

Bin Guan

Lee S Weinstein

Haobin Chen

William F Simonds

Affiliations

Soon will be listed here.

Abstract

Mutation of the CDC73 gene, which encodes parafibromin, has been linked with parathyroid cancer. However, no correlation between genotypes of germline CDC73 mutations and the risk of parathyroid cancer has been known. In this study, subjects with germline CDC73 mutations were identified from the participants of two clinical protocols at National Institutes of Health (Discovery Cohort) and from the literature (Validation Cohort). The relative risk of developing parathyroid cancer was analyzed as a function of CDC73 genotype, and the impact of representative mutations on structure of parafibromin was compared between genotype groups. A total of 419 subjects, 68 in Discovery Cohort and 351 in Validation Cohort, were included. In both cohorts, percentages of CDC73 germline mutations that predicted significant conformational disruption or loss of expression of parafibromin (referred as 'high-impact mutations') were significantly higher among the subjects with parathyroid cancers compared to all other subjects. The Kaplan-Meier analysis showed that high-impact mutations were associated with a 6.6-fold higher risk of parathyroid carcinoma compared to low-impact mutations, despite a similar risk of developing primary hyperparathyroidism between two groups. Disruption of the C-terminal domain (CTD) of parafibromin is directly involved in predisposition to parathyroid carcinoma, since only the mutations impacting this domain were associated with an increased risk of parathyroid carcinoma. Structural analysis revealed that a conserved surface structure in the CTD is universally disrupted by the mutations affecting this domain. In conclusion, high-impact germline CDC73 mutations were found to increase risk of parathyroid carcinoma by disrupting the CTD of parafibromin.

Citing Articles

The prognostic value of ultrasound features and parafibromin expression in parathyroid carcinoma.

Liu R, Ma L, Xia Y, Gao L, Ji J, An Y Orphanet J Rare Dis. 2025; 20(1):100.

PMID: 40038693 PMC: 11881409. DOI: 10.1186/s13023-025-03608-4.

Use of Olaparib in the Management of Metastatic Parathyroid Carcinoma With Mutation.

Woodfield D, Le T, Prince G, Lee H, Vachhani H, Majety P JCEM Case Rep. 2025; 3(3):luaf007.

PMID: 39963301 PMC: 11831516. DOI: 10.1210/jcemcr/luaf007.

A Novel Pathogenic Gene Variant in Hyperparathyroidism-jaw Tumor Syndrome.

Ishida Y, Hirose R, Nakano M, Tsurutani Y JCEM Case Rep. 2025; 3(2):luaf016.

PMID: 39866915 PMC: 11758138. DOI: 10.1210/jcemcr/luaf016.

The Delicate Balancing of Pros and Cons in the Surgical Management of Hyperparathyroidism in a Young Female with Germline Variant in the CDC73 Gene.

Steyaert L, David K, Breckpot J, Renard M, Vander Poorten V, Decallonne B Calcif Tissue Int. 2025; 116(1):21.

PMID: 39751933 PMC: 11698747. DOI: 10.1007/s00223-024-01334-w.

c.1155-3A>G is a pathogenic variant that causes aberrant splicing, disrupted parafibromin expression, and hyperparathyroidism-jaw tumor syndrome.

Needleman L, Chun N, Sitaraman S, Tan M, Sellmeyer D, Kebebew E JBMR Plus. 2024; 9(1):ziae149.

PMID: 39677927 PMC: 11646312. DOI: 10.1093/jbmrpl/ziae149.

References

Li Y, Simonds W . Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocr Relat Cancer. 2016; 23(6):R229-47. PMC: 4917437. DOI: 10.1530/ERC-16-0059. View

Panicker L, Zhang J, Dagur P, Gastinger M, Simonds W . Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. Endocr Relat Cancer. 2010; 17(2):513-24. PMC: 3098453. DOI: 10.1677/ERC-09-0272. View

Mosimann C, Hausmann G, Basler K . The role of Parafibromin/Hyrax as a nuclear Gli/Ci-interacting protein in Hedgehog target gene control. Mech Dev. 2009; 126(5-6):394-405. DOI: 10.1016/j.mod.2009.02.002. View

Lee P, Jarosek S, Virnig B, Evasovich M, Tuttle T . Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007; 109(9):1736-41. DOI: 10.1002/cncr.22599. View

Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R . The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996; 276(19):1575-9. View

Hahn M, Marsh D . Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Lett. 2007; 581(26):5070-4. DOI: 10.1016/j.febslet.2007.09.050. View

Sun W, Kuang X, Liu Y, Tian L, Yan X, Xu W . Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Sci Rep. 2017; 7(1):15638. PMC: 5688130. DOI: 10.1038/s41598-017-15715-9. View

Amrich C, Davis C, Rogal W, Shirra M, Heroux A, Gardner R . Cdc73 subunit of Paf1 complex contains C-terminal Ras-like domain that promotes association of Paf1 complex with chromatin. J Biol Chem. 2012; 287(14):10863-75. PMC: 3322841. DOI: 10.1074/jbc.M111.325647. View

Wei Z, Sun B, Wang Z, He J, Fu W, Fan Y . Whole-Exome Sequencing Identifies Novel Recurrent Somatic Mutations in Sporadic Parathyroid Adenomas. Endocrinology. 2018; 159(8):3061-3068. DOI: 10.1210/en.2018-00246. View

10.

Iwata T, Mizusawa N, Taketani Y, Itakura M, Yoshimoto K . Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene. 2007; 26(42):6176-83. DOI: 10.1038/sj.onc.1210445. View

11.

Rodrigo J, Hernandez-Prera J, Randolph G, Zafereo M, Hartl D, Silver C . Parathyroid cancer: An update. Cancer Treat Rev. 2020; 86:102012. DOI: 10.1016/j.ctrv.2020.102012. View

12.

Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven T, Roeher H . Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med. 2003; 349(16):1517-25. DOI: 10.1056/NEJMoa012915. View

13.

Clarke C, Katsonis P, Hsu T, Koire A, Silva-Figueroa A, Christakis I . Comprehensive Genomic Characterization of Parathyroid Cancer Identifies Novel Candidate Driver Mutations and Core Pathways. J Endocr Soc. 2019; 3(3):544-559. PMC: 6372985. DOI: 10.1210/js.2018-00043. View

14.

Cui M, Hu Y, Bi Y, Wang W, Wang M, Zhang X . Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas. Int J Cancer. 2018; 144(3):525-532. DOI: 10.1002/ijc.31948. View

15.

Wei C, Harari A . Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012; 13(1):11-23. DOI: 10.1007/s11864-011-0171-3. View

16.

Hahn M, Marsh D . Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene. 2005; 24(41):6241-8. DOI: 10.1038/sj.onc.1208778. View

17.

Gill A, Lim G, Cheung V, Andrici J, Perry-Keene J, Paik J . Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features. Am J Surg Pathol. 2018; 43(1):35-46. PMC: 6296846. DOI: 10.1097/PAS.0000000000001017. View

18.

Pazienza V, la Torre A, Baorda F, Alfarano M, Chetta M, Muscarella L . Identification and functional characterization of three NoLS (nucleolar localisation signals) mutations of the CDC73 gene. PLoS One. 2013; 8(12):e82292. PMC: 3855386. DOI: 10.1371/journal.pone.0082292. View

19.

Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R . Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab. 1996; 81(5):1780-3. DOI: 10.1210/jcem.81.5.8626834. View

20.

Mosimann C, Hausmann G, Basler K . Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell. 2006; 125(2):327-41. DOI: 10.1016/j.cell.2006.01.053. View